person · Reporting owner
Dewhurst Martin William
Disclosed activity across 2 companies
Sign in to followReported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| NovaBridge BiosciencesNBP · Entity 6324 | Director | September 08, 2026 | September 10, 2026 |
| Turn Therapeutics Inc.TTRX · Entity 5935 | Director | June 04, 2026 | June 08, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
NovaBridge Biosciences
Report date September 08, 2026 · Filed September 10, 2026
This filing explicitly reported no securities owned.
Turn Therapeutics Inc.
Report date June 04, 2026 · Filed June 08, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $5.75 · Expires 2036-06-04 | Direct | 71,666 |
Reported balance
After 2026-06-04 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-06-04 · Grant · Acquired 71,666 · Balance 71,666 F1: The option will vest in twelve (12) equal monthly installments, on the last day of each calendar month, commencing on June 30, 2026, subject to the Reporting Person's continued employment and the terms and conditions of the applicable option award and the Issuer's 2025 Omnibus Incentive Plan. |
Filing footnotes · ownership attribution and instrument terms
F1: The option will vest in twelve (12) equal monthly installments, on the last day of each calendar month, commencing on June 30, 2026, subject to the Reporting Person's continued employment and the terms and conditions of the applicable option award and the Issuer's 2025 Omnibus Incentive Plan.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| June 04, 2026 Filed Jun 8, 2026 21:31 UTC | Turn Therapeutics Inc. TTRX · Entity 5935 | GrantStock option (right to buy) · Derivative | 71,666 | $0.00 Strike: $5.75 | $0.00 |
DisclosureSEC source: 0001213900-26-066395 · ownership.xml · derivative · entry 1 Dewhurst Martin William · CIK 0002108597 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 71,666 Underlying: Common Stock · 71,666 shares Expires 2036-06-04 F1 · derivative.exercise_date: The option will vest in twelve (12) equal monthly installments, on the last day of each calendar month, commencing on June 30, 2026, subject to the Reporting Person's continued employment and the terms and conditions of the applicable option award and the Issuer's 2025 Omnibus Incentive Plan. Read SEC document |
| January 07, 2026 Filed Feb 4, 2026 12:31 UTC | Turn Therapeutics Inc. TTRX · Entity 5935 | GrantCommon Stock | 21,882 | $0.00 | $0.00 |
DisclosureSEC source: 0001213900-26-011817 · ownership.xml · nonDerivative · entry 1 Dewhurst Martin William · CIK 0002108597 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 21,882 F1 · balance_after: The securities reported in Column 5 of Table I are restricted stock units ("RSU"). Each RSU represents a contingent right to receive one share of common stock, subject to the applicable vesting schedule and conditions of the applicable RSU award and the Issuer's 2025 Omnibus Incentive Plan. The 21,882 RSUs included in Column 5 of Table I vest in full on January 7, 2027, subject to the reporting person's continuous service to the Issuer. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.